For the quarter ending 2026-04-03, EXEL has $2,593,593K in assets. $657,845K in debts. $226,152K in cash and cash equivalents.
| Balance Sheets | 2026-04-03 | 2026-01-02 | 2025-10-03 | 2025-07-04 |
|---|---|---|---|---|
| Cash and cash equivalents | 226,152 | 482,488 | 376,300 | 164,433 |
| Marketable securities | 551,055 | 576,603 | 612,235 | 626,665 |
| Trade receivables, net | 328,947 | 286,916 | 309,725 | 292,354 |
| Inventory | 26,605 | 21,686 | 27,402 | 23,483 |
| Prepaid expenses and other current assets | 75,878 | 75,596 | 76,595 | 73,829 |
| Total current assets | 1,208,637 | 1,443,289 | 1,402,257 | 1,180,764 |
| Non-current marketable securities | 649,144 | 603,603 | 578,287 | 594,652 |
| Property and equipment, net | 95,524 | 98,960 | 104,748 | 110,314 |
| Deferred tax assets, net | 293,730 | 292,582 | 418,582 | 419,241 |
| Goodwill | 63,684 | 63,684 | 63,684 | 63,684 |
| Right-of-use assets and other non-current assets | 282,874 | 342,305 | 255,989 | 309,426 |
| Total assets | 2,593,593 | 2,844,423 | 2,823,547 | 2,678,081 |
| Accounts payable | 24,154 | 29,623 | 25,348 | 25,821 |
| Accrued compensation and benefits | 87,512 | 102,218 | 104,364 | 72,250 |
| Accrued clinical trial liabilities | 64,804 | 65,742 | 57,781 | 57,874 |
| Rebates and fees due to customers | 65,892 | 59,896 | 58,234 | 57,276 |
| Accrued collaboration liabilities | 28,327 | 22,783 | 23,428 | 21,525 |
| Other current liabilities | 100,286 | 125,382 | 104,622 | 101,365 |
| Total current liabilities | 370,975 | 405,644 | 373,777 | 336,111 |
| Non-current operating lease liabilities | 169,541 | 173,038 | 176,463 | 179,842 |
| Other non-current liabilities | 117,329 | 104,422 | 112,607 | 128,592 |
| Total liabilities | 657,845 | 683,104 | 662,847 | 644,545 |
| Common stock, 0.001 par value 400,000 shares authorized issued and outstanding 253,701 and 262,483 at march 31, 2026, and december 31, 2025, respectively | 254 | 262 | 268 | 270 |
| Additional paid-in-capital | 2,151,703 | 2,234,411 | 2,262,928 | 2,251,456 |
| Accumulated other comprehensive income (loss) | -415 | 3,476 | 3,565 | 1,349 |
| Accumulated deficit | -215,794 | -76,830 | -106,061 | -219,539 |
| Total stockholders equity | 1,935,748 | 2,161,319 | 2,160,700 | 2,033,536 |
| Total liabilities and stockholders equity | 2,593,593 | 2,844,423 | 2,823,547 | 2,678,081 |
EXELIXIS, INC. (EXEL)
EXELIXIS, INC. (EXEL)